The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 02, 2019
Filed:
Sep. 14, 2016
Applicant:
Glaxosmithkline Biologicals S.a., Rixensart, BE;
Inventors:
Ralph Leon Biemans, Rixensart, BE;
Dominique Boutriau, Rixensart, BE;
Carine Capiau, Rixensart, BE;
Philippe Denoel, Rixensart, BE;
Pierre Duvivier, Rixensart, BE;
Jan Poolman, Rixensart, BE;
Assignee:
GLAXOSMITHKLINE BIOLOGICALS S.A., Rixensart, BE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/02 (2006.01); C07H 3/00 (2006.01); C12N 7/00 (2006.01); A61K 39/08 (2006.01); A61K 39/09 (2006.01); A61K 39/385 (2006.01); A61K 39/095 (2006.01); A61K 39/102 (2006.01); A61K 39/116 (2006.01); A61K 39/05 (2006.01); A61K 39/29 (2006.01); A61K 39/145 (2006.01); A61K 39/12 (2006.01);
U.S. Cl.
CPC ...
A61K 39/385 (2013.01); A61K 39/0017 (2013.01); A61K 39/0018 (2013.01); A61K 39/05 (2013.01); A61K 39/08 (2013.01); A61K 39/092 (2013.01); A61K 39/095 (2013.01); A61K 39/099 (2013.01); A61K 39/102 (2013.01); A61K 39/116 (2013.01); A61K 39/145 (2013.01); A61K 39/292 (2013.01); C07H 3/00 (2013.01); C12N 7/00 (2013.01); A61K 39/12 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/62 (2013.01); A61K 2039/627 (2013.01); A61K 2039/70 (2013.01); C12N 2730/10134 (2013.01); C12N 2760/16234 (2013.01); C12N 2760/16271 (2013.01); C12N 2770/32634 (2013.01); Y02A 50/466 (2018.01); Y02A 50/472 (2018.01); Y02A 50/484 (2018.01);
Abstract
The present application discloses an immunogenic composition comprising at least 2 differentcapsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are directly conjugated to a carrier protein(s).